Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus

Abstract

Background

Antiphospholipid syndrome (APS) is an acquired thrombophilia that affects young productive individuals, with permanent damage and negative impact on quality of life. Recently, a damage index specific for APS (DIAPS) was developed. There are, however, no data regarding the comparison of its performance and long-term damage in primary antiphospholipid syndrome (PAPS) and APS related to systemic lupus erythematosus (SLE; APS + SLE). The primary purpose of this study was therefore to compare the long-term damage in patients with these conditions.

Methods

This is a retrospective analysis of a single tertiary center cohort followed for approximately 10 years using a standardized prospective electronic chart database. Fifty consecutive PAPS patients age matched with 50 APS+SLE patients were consecutively selected for the study, and DIAPS was calculated once a year during follow-up. Long-term damage and damage kinetics in both groups were compared.

Results

PAPS and APS + SLE had comparable age (47.10 ± 12.4 vs. 44.04 ± 10.80 years; p = 0.19) and time of follow-up (9.40 ± 3.60 vs. 10.94 ± 4.50 years; p = 0.06). At diagnosis, PAPS had higher DIAPS than APS + SLE (1.72 ± 1.17 vs. 0.82 ± 0.96; p < 0.001). At the end of the 10-year follow-up, both groups presented comparable mean damage scores (2.04 ± 1.50 vs. 2.24 ± 1.61; p = 0.52). The damage increment throughout the observation period for PAPS was solely 35%, whereas for APS + SLE it was gradual, persistent and reached 139% at the end of follow-up, with a total damage increment for PAPS lower than APS + SLE (0.43 ± 0.30 vs. 1.22 ± 1.24; p < 0.001). Of note, the frequency of individuals who acquired damage was lower in PAPS than in APS + SLE (32% vs. 71%; p < 0.001). PAPS also had a longer delay in diagnosis than APS + SLE (4.00 ± 4.20 vs. 2.54 ± 3.05 years; p = 0.04). This delay was positively correlated with a higher damage score at diagnosis (r = 0.36, p < 0.001) in all groups.

Conclusion

We identified a distinct pattern of damage in PAPS and APS related to SLE. Damage in PAPS is an early event, while APS+SLE is associated with higher long-term damage, with a striking increment of damage along the follow-up. A diagnosis delay is correlated with higher damage scores. Damage surveillance therefore requires different approaches for these two conditions.

Keywords

Damage Damage Index for APS antiphospholipid syndrome systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Sangle

Smock

. Antiphospholipid antibody syndrome. Arch Pathol Lab Med 2011; 135: 1092–1096.

Grika

Ziakas

Zintzaras

Moutsopoulos

Vlachoyiannopoulos

. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39: 516–523.

Ruiz-Irastorza

Egurbide

M-V

Ugalde

Aguirre

. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77–82.

Gonçalves

Sousa

Inês

, et al. Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. Lupus 2015; 24: 256–262.

Gladman

Ginzler

Goldsmith

, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

Gladman

Goldsmith

Urowitz

, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 2000; 27: 373–376.

Barbhaiya

Erkan

. The optimal tool for assessment of organ damage in antiphospholipid syndrome. J Rheumatol 2013; 40: 89–89.

Vlachoyiannopoulos

. Dr. Vlachoyiannopoulos replies. J Rheumatol 2013; 40: 90–90.

Amigo

M-C

Goycochea-Robles

Espinosa-Cuervo

, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus 2015; 24: 927–934.

10.

Zuily

Rat

A-C

Regnault

, et al. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus 2015; 24: 1161–1168.

11.

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

12.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

13.

Clinimetrics. By A. R. Feinstein. (Pp. 272; illustrated; £25.00.) Yale University Press: London. 1987. Psychol Med 1988; 18: 248–248.

14.

Legge

Doucette

Hanly

. Predictors of organ damage progression and effect on health-related quality of life in systemic lupus erythematosus. J Rheumatol 2016; 43: 1050–1056.

15.

Bruce

O’Keeffe

Farewell

, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015; 74: 1706–1713.

16.

Abreu

Danowski

Wahl

, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14: 401–414.

17.

Amezcua-Guerra

. Improving definitions for an index of cumulative organ damage in patients with the antiphospholipid syndrome (DIAPS). Lupus 2016; 25: 671–672.

18.

Taraborelli

Reggia

Dall’Ara

, et al. Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol 2017; 44: 1165–1172.

19.

Erkan

Yazici

Sobel

Lockshin

. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 2000; 27: 2817–2821.

20.

Shah

Khamashta

Atsumi

Hughes

. Outcome of patients with anticardiolipin antibodies: a 10 years follow-up of 52 patients. Lupus 1998; 7: 3–6.

21.

Dall’ara

Reggia

Taraborelli

, et al. Patients with longstanding primary antiphospholipid syndrome: Retrospective analysis of organ damage and mortality. Lupus 2014; 23: 1255–1258.

22.

Gergianaki

Bertsias

. Systemic lupus erythematosus in primary care: an update and practical messages for the general practitioner. Front Med 2018; 5: 161–161.

23.

Cervera

Boffa

M-C

Khamashta

Hughes

. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889–893.

24.

Pengo

Ruffatti

Legnani

, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–242.

25.

Alba

Gómez-Puerta

Goycochea-Robles

Amigo

. Organ damage and quality of life in antiphospholipid syndrome. Curr Rheumatol Rep 2016; 18: 7–7.

26.

Rump

Lang

Engler

Peter

. Primary antiphospholipid syndrome (PAPS). Two case reports and therapeutic implications. Rheumatol Int 1991; 10: 255–260.

27.

Sciascia

Murru

Sanna

Roccatello

Khamashta

Bertolaccini

. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012; 10: 2512–8.

28.

Ansell

Hirsh

Poller

Bussey

Jacobson, Hylek

. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S–233S.